Xenon Files NDA for Azetukalner in Focal Seizures, Pauses Psych Enrollment
XENE sits 56% above its 52-week low of $35.97.
Summary
Xenon has filed an NDA with the FDA for azetukalner in focal seizures, backed by Phase 2b and Phase 3 data. The company has paused new enrollment in MDD/BPD studies to assess neuropsychiatric adverse events, introducing uncertainty for the psychiatry expansion. Topline X-NOVA2 data are now expected in Q1 2027, a delay from prior expectations. The core epilepsy program continues unaffected, supporting the near-term regulatory path. This follows a Q2 2026 net loss of $1.11 per share and recent insider selling.
At the time of this announcement, XENE was trading at $56.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.6B. The 52-week trading range was $35.97 to $72.66. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.